Adagio Medical Holdings, Inc. (ADGM): Nasdaq/NYSE listing notice — Director resigns; Adagio Medical to be non-compliant with Nasdaq audit committee rule

Adagio Medical Holdings, Inc.

Shahram Moaddeb resigns as director effective Jan 1, 2025, citing demands of other business ventures; no dispute with company.
Resignation leaves audit committee with a vacancy, triggering non-compliance with Nasdaq Listing Rule 5605(c)(2)(A) as of Jan 1, 2025.
Company notified Nasdaq on Dec 20, 2024 of expected non-compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Adagio Medical Holdings, Inc. received a nasdaq noncompliance notice notice regarding audit committee (rules 5605(c)(2)(A)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: audit committee
Rules: 5605(c)(2)(A)

Exact text from the filing

December 20, 2024, Adagio Medical Holdings, Inc., a Delaware corporation (the “Company”), notified the Nasdaq Stock Market LLC (“Nasdaq”) that the Company will not be in compliance with the audit committee requirement under Nasdaq Listing Rule 5605(c)(2)(A) as of January 1, 2025, solely due to a vacancy on the audit committee (the “Audit Committee”) of the Company’s Board of Directors (the “Board”) resulting from Shahram Moaddeb’s resignation from the Board as disclosed in

View on SEC.gov

19 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Adagio Medical Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-016460

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.